Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-0425PMID 18245544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.

  2007cited by this paper
• Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics

  2006cited by this paper
• Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients

  2006cited by this paper
• A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation

  2006cited by this paper
• Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

  2006cited by this paper
• Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

  2006cited by this paper
• A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer

  2006cited by this paper
• Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.

  2006cited by this paper
• Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia.

  2006cited by this paper
• Influence of combined methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase enhancer region (TSER) polymorphisms to plasma homocysteine levels in Korean patients with recurrent spontaneous abortion.

  2006cited by this paper
• The MTHFR 1298CC and 677TT genotypes have opposite associations with red cell folate levels.

  2006cited by this paper
• Studying the predictive/prognostic role of thymidylate synthase genotypes in patients with colorectal cancer: Is one polymorphism enough?

  2005cited by this paper
• Methylenetetrahydrofolate Reductase in Coronary Artery Disease

  2005cited by this paper
• Prognostic Role of Thymidylate Synthase Polymorphisms in Gastric Cancer Patients Treated with Surgery and Adjuvant Chemotherapy

  2005cited by this paper
• Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.

  2005cited by this paper
• A common insertion/deletion polymorphism of the thymidylate synthase (TYMS) gene is a determinant of red blood cell folate and homocysteine concentrations

  2005cited by this paper
• Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.

  2005cited by this paper
• Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

  2004cited by this paper
• Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy

  2004cited by this paper
• A haplotype of the methylenetetrahydrofolate reductase gene is protective against late-onset Alzheimer's disease.

  2004cited by this paper
• Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.

  2004cited by this paper
• A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels.

  2004cited by this paper
• Activity Gene Abolishes USF-1 Binding and Alters Transcriptional Thymidylate Synthase Tandem Repeat Polymorphism of the ′ A Novel Single Nucleotide Polymorphism within the 5

  2003cited by this paper
• The thymidylate synthase tandem repeat polymorphism is not associated with homocysteine concentrations in healthy young subjects

  2003cited by this paper
• Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.

  2003cited by this paper
• Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.

  2003cited by this paper
• 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview.

  2003cited by this paper
• Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer.

  2003cited by this paper
• Understanding the Cancer Biology Universe: Enigmas, Context and Future Prospects

  2002cited by this paper
• Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease

  2002cited by this paper
• Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

  2002cited by this paper
• Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels

  2002influential reference
• Caution on pedigree haplotype inference with software that assumes linkage equilibrium.

  2002cited by this paper
• Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease.

  2001cited by this paper
• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  2001cited by this paper
• The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine.

  2001cited by this paper
• A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil

  2001cited by this paper
• Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.

  2001cited by this paper
• Methylenetetrahydrofolate reductase polymorphism is associated with folate pool in gastrointestinal cancer tissue.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Folic acid: nutritional biochemistry, molecular biology, and role in disease processes.

  2000cited by this paper
• Fluoropyrimidines: A Critical Evaluation

  1999cited by this paper
• Multiple imputation: a primer

  1999cited by this paper
• Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.

  1999cited by this paper
• Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

  1999cited by this paper
• Warfarin—5‐FU Interaction — A Consecutive Case Series

  1999cited by this paper
• Multiple imputation of missing blood pressure covariates in survival analysis.

  1999cited by this paper
• Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

  1999cited by this paper
• Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.

  1999influential reference
• A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations.

  1999cited by this paper
• A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.

  1998cited by this paper
• p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.

  1998cited by this paper
• DNA instability (strand breakage, uracil misincorporation, and defective repair) is increased by folic acid depletion in human lymphocytes in vitro

  1998cited by this paper
• A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

  1998cited by this paper
• Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

  1998cited by this paper
• Decreased methylene tetrahydrofolate reductase activity due to the 677C→T mutation in families with spina bifida offspring

  1997cited by this paper
• Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients.

  1997cited by this paper
• Low concentrations of folate in serum and erythrocytes of smokers: methionine loading decreases folate concentrations in serum of smokers and nonsmokers.

  1997cited by this paper
• Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

  1997cited by this paper
• Transcriptional repression by methylation: cooperativity between a CpG cluster in the promoter and remote CpG‐rich regions

  1996cited by this paper
• Decreased methylene tetrahydrofolate reductase activity due to the 677C→T mutation in families with spina bifida offspring

  1996cited by this paper
• A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

  1995cited by this paper
• Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida.

  1995cited by this paper
• Fluorouracil: biochemistry and pharmacology.

  1988cited by this paper
• Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA.

  1987influential reference
• Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.

  1981cited by this paper
• Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism.

  1978cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Problems of Reporting Genetic Associations with Complex Outcomes

  year unknowncited by this paper

• Integrated molecular and microenvironmental drivers of drug resistance in gastrointestinal cancers: mechanisms, immunotherapy challenges, and precision strategies

  2025cites this paper
• 5-Fluorouracil (5-FU)-induced organ toxicities: mechanisms, management, and prevention strategies

  2025cites this paper
• Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review

  2024cites this paper
• Folate, folic acid, and chemotherapy-induced toxicities: a systematic literature review.

  2023cites this paper
• Biomarkers in Colorectal Cancer: Recent Investigation and Future Prospective

  2023cites this paper
• Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study

  2023cites this paper
• Predicting Severe Haematological Toxicity in Gastrointestinal Cancer Patients Undergoing 5-FU-Based Chemotherapy: A Bayesian Network Approach

  2023cites this paper
• Metabolic reprogramming in cancer: Mechanisms and therapeutics

  2023cites this paper
• Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation

  2022influential citation
• Predictive “omic” biomarkers of drug response: Colorectal cancer as a model

  2022cites this paper
• Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation

  2021cites this paper
• The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens

  2021cites this paper
• Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes

  2021cites this paper
• Immunohistochemical and genetic prognostic factors of neoadjuvant chemoradiotherapy efficаcy in personalized treatment of local advanced rectal cancer.

  2020cites this paper
• A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies

  2020cites this paper
• Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.

  2020cites this paper
• Biomarkers in Colorectal Cancer: Current Research and Future Prospects

  2020cites this paper
• Association of C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine-induced Toxicity in Mestizo Patients With Metastatic Colorectal Cancer

  2020cites this paper
• The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population

  2020cites this paper
• 5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine

  2020cites this paper
• Methylene tetrahydrofolate reductase (MTHFR) gene rs1801133 C>T polymorphisms and response to 5-FU based chemotherapy in patients with colorectal cancer: a meta-analysis

  2019cites this paper
• A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant

  2019cites this paper
• Methylenetetrahydrofolate reductase polymorphisms and colorectal cancer prognosis: A meta‐analysis

  2019cites this paper
• 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.

  2019cites this paper
• SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand

  2018cites this paper
• GSTP1, TSER, MTHFR C677T and MTHFR A1298C gene single nucleotide polymorphisms associated with toxicity and survival in patients with colorectal cancer treated with 5‑fluorouracil-based chemotherapy

  2018cites this paper
• Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy

  2017cites this paper
• 5-Fluorouracil degradation rate could predict toxicity in stages II–III colorectal cancer patients undergoing adjuvant FOLFOX

  2017cites this paper
• Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer.

  2017cites this paper
• A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient

  2017cites this paper
• Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine

  2017cites this paper
• DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer

  2017cites this paper
• Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?

  2016cites this paper
• Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer

  2016cites this paper
• Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort

  2016cites this paper
• Nucleoside analogs: ready to enter the era of precision medicine?

  2016cites this paper
• The role of pharmacogenetics in capecitabine efficacy and toxicity.

  2016cites this paper
• A PHARMACOGENETIC STUDY OF CAPECITABINE-OXALIPLATIN THERAPY IN COLORECTAL CANCER PATIENTS AMONG SOUTH INDIAN POPULATION

  2016cites this paper
• Germline oncopharmacogenetics, a promising field in cancer therapy

  2015cites this paper
• Identification of genetic markers that predict cancer sensitivity to the anticancer drugs 5-FU and Irinotecan

  2015cites this paper
• Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.

  2015cites this paper
• A phase 1 clinical trial of sequential pralatrexate followed by a 48‐hour infusion of 5‐fluorouracil given every other week in adult patients with solid tumors

  2015cites this paper
• Methylenetetrahydrofolate reductase C677T and overall survival in pediatric acute lymphoblastic leukemia: a systematic review

  2014cites this paper
• Polymorphisms in Genes of Drug Targets and Metabolism

  2014cites this paper
• Distribution of the most Common Genetic Variants Associated with a Variable Drug Response in the Population of the Republic of Macedonia

  2014cites this paper
• Recent studies of 5-fluorouracil resistance in pancreatic cancer.

  2014cites this paper
• Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

  2014cites this paper
• Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

  2014cites this paper
• Déterminants moléculaires et génétiques d’efficacité et de toxicité du 5-fluoro-uracile

  2014cites this paper
• Prediction of Chemotherapy Toxicities

  2013cites this paper
• Pharmacogenomics and Personalized Medicine for Cancer

  2013cites this paper
• MTHFR Glu429Ala and ERCC5 His46His Polymorphisms Are Associated with Prognosis in Colorectal Cancer Patients: Analysis of Two Independent Cohorts from Newfoundland

  2013cites this paper
• Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

  2013cites this paper
• An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens

  2013cites this paper
• Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer

  2013cites this paper
• MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer

  2013cites this paper
• Farmacogenética en el tratamiento del cáncer colorrectal

  2012cites this paper
• Folic acid found to enhance tumor growth : Historical note

  2012cites this paper
• Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation

  2012cites this paper
• Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.

  2012cites this paper
• Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives

  2012cites this paper
• Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis

  2012cites this paper
• Pharmacogenetics and Pharmacogenomics of Colorectal Cancer: Moving Towards Personalized Medicine

  2012cites this paper
• Capecitabine–phenytoin interaction is dose dependent with an unexpected time course

  2011cites this paper
• Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.

  2011cites this paper
• Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.

  2011cites this paper
• Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer

  2011cites this paper
• The impact of folate status on the efficacy of colorectal cancer treatment.

  2011cites this paper
• Determinants of antifolate and 5-fluorouracil efficacy

  2011cites this paper
• Molecular Markers of Chemotherapy Toxicity in Colorectal Cancer

  2011cites this paper
• Adaptation of dosing regimen of chemotherapies based on pharmacodynamic models

  2011cites this paper
• Modulation of One-Carbon Metabolism by B Vitamins: Implications for Transformation and Progression of Prostate Cancer

  2011cites this paper
• Management of capecitabine-related gastrointestinal toxicities in women with breast cancer

  2011cites this paper
• Predictive Biomarkers and Personalized Medicine Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients

  2011cites this paper
• Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

  2011cites this paper
• Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients

  2011cites this paper
• Colorectal Cancer Patients Gastrointestinal Toxicity in Chemotherapy-Treated 5-Fluorouracil Metabolism Pathway Are Associated with Combinations of Polymorphisms in Genes Involved in the Updated

  2011cites this paper
• Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.

  2011cites this paper
• Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

  2011cites this paper
• Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group

  2011cites this paper
• Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients

  2010cites this paper
• Germline determinants of outcome and risk in colorectal cancer

  2010cites this paper
• Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network.

  2010cites this paper
• Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.

  2010cites this paper
• Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis

  2010influential citation
• Clinical Omics Analysis of Colorectal Cancer Incorporating Copy Number Aberrations and Gene Expression Data

  2010cites this paper
• Role of the MTHFR polymorphisms in cancer risk modification and treatment.

  2009cites this paper
• Pharmacogenetics in chemotherapy of colorectal cancer.

  2009cites this paper
• C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.

  2009cites this paper
• Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?

  2009cites this paper
• Pharmacogenetics and biomarkers in colorectal cancer

  2009cites this paper
• Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer

  2009cites this paper
• Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model.

  2009cites this paper
• A study of the MTHFR gene polymorphism C677T in colorectal cancer.

  2009cites this paper
• Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

  2009cites this paper
• Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.

  2009cites this paper
• Genetic prognostic and predictive markers in colorectal cancer

  2009cites this paper
• Pharmacogenetic relevance of MTHFR polymorphisms.

  2008cites this paper
• Determinants of Antifolate and 5‐fluorouracil Efficacy Determinants of Antifolate and 5‐fluorouracil Efficacy

  year unknowncites this paper